Joao Siffert MD

Joao Siffert MD discloses dealings in 4 companies, chiefly Avanir Pharmaceuticals, AveXis, Inc. and Design Therapeutics, Inc. Over a trading history stretching from 15 December 2011 to 20 December 2022, the count stands at 22 filings.

The open-market side counts 3 purchases for €65k alongside 5 sales for €420k. Sales outweigh purchases by €355k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 11 share grants and 2 option exercises. In 2022 alone, the filings show 2 purchases and no sales.

A typical purchase (the median) is worth €9,202.

Most recently, on 21 December 2022, the filings show an open-market purchase worth €50k in Design Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.